These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36512150)

  • 1. Efficiently driving protein-based fragment screening and lead discovery using two-dimensional NMR.
    Peng C; Namanja AT; Munoz E; Wu H; Frederick TE; Maestre-Martinez M; Iglesias Fernandez I; Sun Q; Cobas C; Sun C; Petros AM
    J Biomol NMR; 2023 Apr; 77(1-2):39-53. PubMed ID: 36512150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CcpNmr AnalysisScreen, a new software programme with dedicated automated analysis tools for fragment-based drug discovery by NMR.
    Mureddu LG; Ragan TJ; Brooksbank EJ; Vuister GW
    J Biomol NMR; 2020 Nov; 74(10-11):565-577. PubMed ID: 32638146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMR-based fragment screening and lead discovery accelerated by principal component analysis.
    Namanja AT; Xu J; Wu H; Sun Q; Upadhyay AK; Sun C; Van Doren SR; Petros AM
    J Biomol NMR; 2019 Dec; 73(12):675-685. PubMed ID: 31541395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
    Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
    J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1D and 2D NMR for KRAS:Ligand Binding.
    Cornilescu G
    Methods Mol Biol; 2024; 2797():115-124. PubMed ID: 38570456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy.
    Egner JM; Jensen DR; Olp MD; Kennedy NW; Volkman BF; Peterson FC; Smith BC; Hill RB
    Chembiochem; 2018 Mar; 19(5):448-458. PubMed ID: 29239081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based screening by protein-detected NMR spectroscopy.
    Kerber PJ; Nuñez R; Jensen DR; Zhou AL; Peterson FC; Hill RB; Volkman BF; Smith BC
    Methods Enzymol; 2023; 690():285-310. PubMed ID: 37858532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of Solution NMR in Drug Discovery.
    Shi L; Zhang N
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33499337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GIPMA: Global Intensity-Guided Peak Matching and Alignment for 2D
    Du H; Gu X; Chen J; Bai C; Duan X; Hu K
    Anal Chem; 2023 Feb; 95(6):3195-3203. PubMed ID: 36728684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMR-based screening methods for lead discovery.
    Vogtherr M; Fiebig K
    EXS; 2003; (93):183-202. PubMed ID: 12613177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introducing the CSP Analyzer: A novel Machine Learning-based application for automated analysis of two-dimensional NMR spectra in NMR fragment-based screening.
    Fino R; Byrne R; Softley CA; Sattler M; Schneider G; Popowicz GM
    Comput Struct Biotechnol J; 2020; 18():603-611. PubMed ID: 32257044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A three-stage biophysical screening cascade for fragment-based drug discovery.
    Mashalidis EH; Śledź P; Lang S; Abell C
    Nat Protoc; 2013 Nov; 8(11):2309-24. PubMed ID: 24157549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [NMR screening in fragment-based drug discovery].
    Hanzawa H; Takizawa T
    Yakugaku Zasshi; 2010 Mar; 130(3):325-33. PubMed ID: 20190517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MetaboMiner--semi-automated identification of metabolites from 2D NMR spectra of complex biofluids.
    Xia J; Bjorndahl TC; Tang P; Wishart DS
    BMC Bioinformatics; 2008 Nov; 9():507. PubMed ID: 19040747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
    Li Q; Kang C
    Molecules; 2020 Jun; 25(13):. PubMed ID: 32605297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant Kinase Production and Fragment Screening by NMR Spectroscopy.
    Han B; Ahn HC
    Methods Mol Biol; 2016; 1360():35-46. PubMed ID: 26501900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.